A bioconjugation method to covalently link molecular entities to polypeptides such as antibodies using a simple one-pot process.
Therapeutic compounds, such as antibody-drug conjugates (ADCs), are prepared where the drug bears a reactive functional group (such as maleimide) for attachment to an antibody. The bioconjugation reactions for coupling to native residues (Lys and Cys) in biological molecules have changed very little in the last five to ten years. However, new reactions are becoming more important as second and third generation ADCs are developed for the treatment of diseases. While new bioconjugation chemistries have expanded the strategies for preparing bioconjugates, their applications to prepare therapeutic molecules can be limited due to long reaction times, hydrophobic reaction partners that adversely affect protein properties, and potential safety concerns with explosive intermediates. Therefore, it would be advantageous to have an alternative method of conjugating a biological molecule to another entity that utilizes a functional group that is currently available and known to be compatible with a large range of desired payloads.
Researchers at UC Santa Barbara have developed a bioconjugation method to covalently link molecular entities to polypeptides such as antibodies using a simple one-pot process. Tests show that two cyclopentadiene derivatives could be incorporated site-specifically into an antibody and react with quantitative conversion with the maleimide-drug Vedotin. This reaction can be employed under mild conditions in specific conjugation reactions comprising a biological molecule. In some instances the reaction takes as little as two hours at room temperature with no added reagents or catalysts. The key feature of this strategy is the serum stability of the linkage compared to the commonly used thiol-maleimide bond, potentially improving the pharmacokinetic properties of the ADC. This improved serum stability is independent of the site of incorporation, which would streamline ADC development compared to the THIOMAB strategy.
|United States Of America||Published Application||20-0206359||07/02/2020||2017-467|
conjugating, biological molecule, bioconjugation, ADC, anti-body conjugates, indpharma